netFormulary Bradford Teaching Hospitals NHS
NHS Foundation Trust Formulary  
 Formulary Chapter 14: Immunological products and vaccines - Full Chapter
14.05  Expand sub section  Immunoglobulins
14.05  Expand sub section  Normal immunoglobulin
14.05  Expand sub section  Specific immunoglobulins
14.05  Expand sub section  Anti-D (Rho) immunoglobulin
14.05  Expand sub section  Interferons to top
14.05.01  Expand sub section  Normal immunoglobulin
14.05.02  Expand sub section  Disease-specific immunoglobulins
14.05.03  Expand sub section  Anti-D (Rho) immunoglobulin
 Non Formulary Items
Anti-D (Rh0) Immunoglobulin  (Partobulin SDF®)

View adult BNF View SPC online View childrens BNF
Non Formulary
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to children's BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Medicines suitable to be prescribed in primary care after Specialist* recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust D&TC(s). *Specialist is defined as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice.   

Amber 1

Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (D&TC) * All drugs awaiting the production or approval of a shared care guideline default to RED   

Cancer Drug Fund

Cancer Drug Fund   


Medicines suitable for routine use and can be prescribed within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Green Specialist Initiation

These drugs should be initiated only by a hospital or specialist clinician (GPSi) but there is no requirement for additional monitoring over the general requirements for all medicines. Some may require short or medium specialist monitoring of efficacy or dose titration before transferring in Primary care. The GP should have all the information they require to support continued prescribing.   

Green Specialist Recomendation



Grey - Medicines, which the Drug & therapeutics Committee has actively reviewed and does not recommend for use at present following a review of clinical and/or cost effective data. Grey (assessment in progress) - will be reviewed at a future D&T meeting. Grey (awaiting submission) - The D&T are awaiting a submission from an appropriate practitioner. If you wish to make a submission for this medicine to be added to the formulary please email .   

Non Formulary

Not recommended for prescribing as initial therapy, but can be continued if patient already stable on treatment   


Medicines which should normally be prescribed by specialists only. ** For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care   


Unlicensed Medication